So a random twitter account accuses you of "destroying" their favourite biotech stock, you look at their bio, and find this. SMH

Evercore on possible FTC issues with $NVS $KDNY takeout: We don’t see any. IgAN is crowded, with multiple players in each MOA; KDNY has no commercial products (but note $ONCE !); iptacopan, atrasentan & BION-1301 have "very different MOA".

Well, I totally missed that: Sara Tolaney slide on OS cut by Trop2 expression in Tropics-02, from Evercore's #Asco23 review $GILD $MRK $AZN $DSNKY

Polite comments here, but read between the lines and $ESALY seems pretty scathing of $BIIB.

Several ironies, and lots to say about $NVS $3.5bn takeover of $KDNY. Includes comments from a recent interview @ByMadeleineA did with Eric Dobmeier. Via @evaluatevantage -> $CALT $TVTX

$OMER -8% $CALT +3% $TVTX +6% Also note $VERA (anti-April player) +20% [ $KDNY +56% ]

This looks legit

Atrasentan composition of matter patent expired in 2015, so $NVS takeover endorses $KDNY's additional IP strategy

Also relevant for $ABBV, which took a (then) $6.7m equity position in $KDNY when it sold it rights to atrasentan in 2020; not sure how big a stake that amounted to. $NVS

Watch $CALT $TVTX $OTSKY & $OMER on today's $KDNY takeover by $NVS

When Sting/LADD was all the rage $ADRO did a deal with $NVS, just before its 2015 IPO. In 2020 that failed, and Chinook reversed into $ADRO. New ticker $KDNY. Today $KDNY was sold to... $NVS!

Per Jefferies: $GILD v +ve on evolving lung cancer opportunity for Trodelvy; Trop2 1L NSCLC data (Evoke-02?) coming Q3. Remember earlier rumour had been that Trodelvy failed in Tropics-03 NSCLC cohort and this was being deprioritised.

Well, this week has been interesting.

So, do we follow commercial considerations or do we follow the science? $ARVN (From Stifel note:)

And, just to rub it in, $ALPMF just filed zolbetuximab in Japan $ELEV

What a time for a secondary. Why didn't $ELEV raise when its #Asco23 abstract went live?

Who won and who lost #Asco23? @evaluatevantage analysed all the key movers: $EFTR $VSTM $NVCR $AFMD

$GILD confirmed to me that data from Tropics-03's NSCLC cohort haven't been published. Not aware of any plans to publish. That would be a relevant comparator for $DSNKY $AZN dato in Tropion-lung01, for $MRK Kelun, and for Trodelvy's own Evoke-1 readout.

Too early to answer this Q of course, but does $ARVN ARV-766 work *best* in patients with all 3 mutations co-occurring, or *only* in these patients? Key to understand its potential market.

Reminder, from 2015: $ARVN